Latest news
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock TitanStock Titan · Mon, 10 Aug 2026 20:14:42 GMTIMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 20:09:45 GMTIMDX Looks 289.5% Overvalued on GF Value™ - GuruFocusGuruFocus · Sun, 09 Aug 2026 22:37:47 GMTEarnings Preview: IMDX to Report Financial Results Post-market on August 10 - MoomooMoomoo · Wed, 05 Aug 2026 03:00:20 GMTiMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 11:00:00 GMTIMDX Rises 1.09% to $4.65 as Molecular Diagnostics Play Holds Key Support - Volatility Skew - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 21:36:25 GMT